Elias Sayour

Elias Sayour, M.D.

Assistant Professor

Department: MD-NEUROLOGICAL SURGERY
Business Phone: (352) 273-9000

About Elias Sayour

Elias Sayour, MD, PhD, is an assistant professor in the UF departments of neurosurgery and pediatrics at the University of Florida. He is also a principal investigator of the ribonucleic acid engineering laboratory at the Preston A. Wells, Jr. Center for Brain Tumor Therapy. He received his bachelor’s degree from Fordham University, his medical degree from the University of Buffalo and his doctorate from Duke University.

He completed his residency in pediatrics at Cohen’s Children’s Medical Center in New York and his fellowship at Duke University Medical Center. During his fellowship training, he completed a two-year National Institutes of Health research fellowship in cancer biology and developmental therapeutics. His primary research focus is developing tumor RNA loaded nanocarriers to re-direct host immunity against pediatric brain tumors.

Dr. Sayour is an NIH-funded investigator focused on on developing new nanotech vaccines to reprogram the immune system against cancer cells. He is investigating the use of personalized nanoparticles small enough to deliver essential information to the immune system educating it reject pediatric cancer. Currently his group is investigating the safety and efficacy of this novel vaccine formulation in canines with malignant brain tumors before translation into dedicated human studies.

Dr. Sayour’s work has been nationally recognized by the American Society of Pediatric Hematology-Oncology, National Institutes of Health, and U.S. Department of Defense. He has been the recipient of the Hyundai Hope on Wheels Hope Award, St. Baldrick’s Scholar Award, and the American Brain Tumor Association Discovery Award.

Dr. Sayour is board-certified in general pediatrics and pediatric hematology-oncology.

He has presented his work at several national meetings and is a member of the Children’s Oncology Group, Society of Neuro-Oncology and the American Society of Pediatric Hematology-Oncology.

Board Certifications

  • Pediatrics
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Brain tumor – children

Research Profile

Areas of Interest
  • Immunotherapeutics for CNS malignancies
  • Pediatric brain tumors

Publications

2020
Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma.
Cancer research. 80(3):499-509 [DOI] 10.1158/0008-5472.CAN-19-1577. [PMID] 31723000.
2020
Nanoparticles as immunomodulators and translational agents in brain tumors.
Journal of neuro-oncology. [DOI] 10.1007/s11060-020-03559-9. [PMID] 32757093.
2019
Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy.
Veterinary immunology and immunopathology. 216 [DOI] 10.1016/j.vetimm.2019.109912. [PMID] 31446208.
2019
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nature communications. 10(1) [DOI] 10.1038/s41467-019-11869-4. [PMID] 31488817.
2019
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
ACS nano. 13(12):13884-13898 [DOI] 10.1021/acsnano.9b05037. [PMID] 31730332.
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology. 12(1) [DOI] 10.1186/s13045-019-0756-z. [PMID] 31311607.
2019
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro-oncology. 21(6):730-741 [DOI] 10.1093/neuonc/noz015. [PMID] 30668768.
2019
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy. 27(4):837-849 [DOI] 10.1016/j.ymthe.2018.10.007. [PMID] 30448196.
2019
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
Journal for immunotherapy of cancer. 7(1) [DOI] 10.1186/s40425-019-0809-4. [PMID] 31753028.
2018
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
International journal of molecular sciences. 19(10) [DOI] 10.3390/ijms19102890. [PMID] 30249040.
2018
CD70, a novel target of CAR T-cell therapy for gliomas.
Neuro-oncology. 20(1):55-65 [DOI] 10.1093/neuonc/nox116. [PMID] 28651374.
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
The EMBO journal. 37(23) [DOI] 10.15252/embj.201798772. [PMID] 30322894.
2018
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Nano letters. 18(10):6195-6206 [DOI] 10.1021/acs.nanolett.8b02179. [PMID] 30259750.
2018
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Frontiers in molecular neuroscience. 11 [DOI] 10.3389/fnmol.2018.00082. [PMID] 29643764.
2017
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.
Frontiers in immunology. 8 [DOI] 10.3389/fimmu.2017.01451. [PMID] 29163521.
2017
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Journal of immunology research. 2017 [DOI] 10.1155/2017/3145742. [PMID] 28265580.
2017
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Oncoimmunology. 6(1) [DOI] 10.1080/2162402X.2016.1256527. [PMID] 28197373.
2017
The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma.
Journal of neurosurgery. 127(1):123-131 [DOI] 10.3171/2016.7.JNS16396. [PMID] 27689459.
2017
Translational nanoparticle engineering for cancer vaccines.
Oncoimmunology. 6(10) [DOI] 10.1080/2162402X.2017.1290036. [PMID] 29123947.
2017
Immunotherapy for Pediatric Brain Tumors.
Brain sciences. 7(10) [DOI] 10.3390/brainsci7100137. [PMID] 29065490.
2016
Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia.
Pediatric blood & cancer. 63(10):1856-9 [DOI] 10.1002/pbc.26092. [PMID] 27273469.
2016
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(3):582-95 [DOI] 10.1158/1078-0432.CCR-15-0713. [PMID] 26405194.
2016
FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers.
Histopathology. 69(4):704-7 [DOI] 10.1111/his.12983. [PMID] 27061725.
2015
A novel ELANE gene mutation in a patient with severe congenital neutropenia and intermittent thrombocytopenia.
Pediatric blood & cancer. 62(10):1870-1 [DOI] 10.1002/pbc.25528. [PMID] 25882539.
2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.
Journal for immunotherapy of cancer. 3 [DOI] 10.1186/s40425-015-0058-0. [PMID] 25901285.
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Cancer immunology, immunotherapy : CII. 64(4):419-27 [DOI] 10.1007/s00262-014-1651-7. [PMID] 25555571.
2015
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Oncoimmunology. 4(3) [PMID] 25949916.
View on: PubMed
2015
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Cancer immunology research. 3(4):320-5 [DOI] 10.1158/2326-6066.CIR-14-0100. [PMID] 25387895.
2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII. 62(6):983-7 [DOI] 10.1007/s00262-013-1405-y. [PMID] 23591978.

Grants

Jul 2020 ACTIVE
Remodeling Host Immunity in Oral Cancer with Personalized RNA Nanoparticle Vaccines
Role:
Funding: NATL INST OF HLTH NIDCR
Jul 2020 ACTIVE
Translating Personalized RNA Nanoparticle Vaccines for Oral Cancer
Role: Mentor
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Jul 2020 ACTIVE
RNA-nanoparticle vaccines for pediatric high-grade glioma
Role: Principal Investigator
Funding: CURESEARCH FOR CHILDRENS CANCER
Jun 2020 ACTIVE
Novel immunologic therapy of soft tissue sarcoma
Role:
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2020 ACTIVE
Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
Role: Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Dec 2019 ACTIVE
Nanoparticles targeting genetic translocations in pediatric brain tumors
Role: Principal Investigator
Funding: HYUNDAI HOPE ON WHEELS
Jul 2019 ACTIVE
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Role: Principal Investigator
Funding: Rally Foundation
Jul 2019 ACTIVE
Re-programming immunity to target mutations across medulloblastoma subtypes
Role: Principal Investigator
Funding: ST BALDRICKS FOUNDATION
Jan 2019 ACTIVE
Development of personalized RNA loaded nano particles for children with refractory solid tumors.
Role: Principal Investigator
Funding: UF FOU via MULTIPLE SPONSORS
Jul 2018 ACTIVE
Legacy Foundation
Role: Project Manager
Funding: UF FOU
Jul 2018 – Jun 2020
Host Immunomodulatory RNA-nanoparticles targeting malignant canine glioma
Role: Principal Investigator
Funding: UF FOU
Jan 2018 – Jun 2020
Development of Personalized RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR via NATL PEDIATRIC CANCER FOU
Sep 2017 – Sep 2020
RNA-nanoparticles targeting H3.3 K27M epitopes in diffuse intrinsic pontine glioma
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Sep 2017 ACTIVE
UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
Role: Project Manager
Funding: MULTIPLE SPONSORS
Jul 2017 – Dec 2019
Immunotherapeutic targeting of osteosarcoma neoantigens
Role: Principal Investigator
Funding: Rally Foundation
Apr 2017 ACTIVE
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Sep 2016 ACTIVE
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting Glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2016 – Jun 2020
Re-programming immunity to target mutations across medulloblastoma subtypes
Role: Principal Investigator
Funding: ST BALDRICKS FOUNDATION
Jul 2016 – Jun 2020
RNA nanoparticle vaccines targeting malignant canine gliomas
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Apr 2016 – Mar 2018
Re-programming osteosarcoma immune evasion
Role: Principal Investigator
Funding: UF FOU
Dec 2014 – Jun 2017
Hyundai Hope on Wheels
Role: Principal Investigator
Funding: HYUNDAI HOPE ON WHEELS
Jul 2013 ACTIVE
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
Role: Project Manager
Funding: FL DEPT OF HLTH

Education

Fellowship – Pediatric Hematology/Oncology
2013 · Duke University
Residency – Pediatrics
2010 · Long Island Jewish Medical Center
Medical Degree
2007 · University at Buffalo

Teaching Profile

Courses Taught
2020
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2017-2020
GMS6065 Fundamentals of Cancer Biology
2018
MDT7400 Elect Top/Pediatrics
2018
MDC7400 Pediatric Clerkship
2018
BME7980 Research for Doctoral Dissertation

Contact Details

Phones:
Business:
(352) 273-9000